Akeso マネジメント

マネジメント基準チェック /44

Akesoの CEO はMichelle Xiaで、 Mar2012年に任命され、の在任期間は 13.83年です。の年間総報酬はCN¥ 5.55Mで、 85.4%給与と14.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の8.15%を直接所有しており、その価値は$ 1.09B 。経営陣と取締役会の平均在任期間はそれぞれ3.4年と6.2年です。

主要情報

Michelle Xia

最高経営責任者

CN¥5.5m

報酬総額

CEO給与比率	85.40%
CEO在任期間	13.8yrs
CEOの所有権	8.2%
経営陣の平均在職期間	3.4yrs
取締役会の平均在任期間	6.2yrs

経営陣の近況

Recent updates

CEO報酬分析

Akeso の収益と比較して、Michelle Xia の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2025	n/a	n/a	-CN¥846m
Mar 31 2025	n/a	n/a	-CN¥680m
Dec 31 2024	CN¥6m	CN¥5m	-CN¥515m
Sep 30 2024	n/a	n/a	-CN¥625m
Jun 30 2024	n/a	n/a	-CN¥735m
Mar 31 2024	n/a	n/a	CN¥646m
Dec 31 2023	CN¥7m	CN¥4m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥409m
Dec 31 2022	CN¥5m	CN¥4m	-CN¥1b
Sep 30 2022	n/a	n/a	-CN¥1b
Jun 30 2022	n/a	n/a	-CN¥1b
Mar 31 2022	n/a	n/a	-CN¥1b
Dec 31 2021	CN¥7m	CN¥4m	-CN¥1b
Sep 30 2021	n/a	n/a	-CN¥1b
Jun 30 2021	n/a	n/a	-CN¥929m
Mar 31 2021	n/a	n/a	-CN¥983m
Dec 31 2020	CN¥7m	CN¥3m	-CN¥1b
Sep 30 2020	n/a	n/a	-CN¥870m
Jun 30 2020	n/a	n/a	-CN¥703m
Mar 31 2020	n/a	n/a	-CN¥492m
Dec 31 2019	CN¥2m	CN¥1m	-CN¥282m

報酬と市場: Michelleの総報酬 ($USD 797.76K ) は、 US市場 ($USD 13.43M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Michelleの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Michelle Xia (58 yo)

13.8yrs

在職期間

CN¥5,548,000

報酬

Dr. Yu Xia, Ph D., also known as Michelle, is CEO & President of Akeso Biopharma, Inc. Dr. Xia is Founder of Akeso, Inc. Dr. Xia is CEO, President & Chairwoman of Akeso, Inc. from March 19, 2012. She has b...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Yu Xia	Founder	13.8yrs	CN¥5.55m	8.15% $ 1.1b
Baiyong Li	Co-Founder	13.8yrs	CN¥5.28m	5.34% $ 714.8m
Zhongmin Wang	Co-Founder	no data	CN¥3.96m	4.65% $ 622.1m
Peng Zhang	Co-Founder	no data	CN¥3.83m	データなし
Yu Xia	Senior Vice President	1.3yrs	CN¥9.33m	データなし
Bing Wang	Chief Financial Officer	1.5yrs	データなし	データなし
Mingxiu Hu	Senior Vice President	4yrs	データなし	データなし
Xinfeng Zhang	Senior Vice President	5.5yrs	データなし	データなし
Jing Min	Senior Vice President	3yrs	データなし	データなし
Yong Guo	Senior VP & Chief Commercial Officer	2yrs	データなし	データなし
Wai Yan Leung	Company Secretary	3.4yrs	データなし	データなし

3.4yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: AKES.Fの経営陣は経験豊富であると考えられます ( 3.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Yu Xia	Founder	13.8yrs	CN¥5.55m	8.15% $ 1.1b
Baiyong Li	Co-Founder	6.2yrs	CN¥5.28m	5.34% $ 714.8m
Zhongmin Wang	Co-Founder	6.2yrs	CN¥3.96m	4.65% $ 622.1m
Peng Zhang	Co-Founder	1.6yrs	CN¥3.83m	データなし
Bo Tan	Independent Non-Executive Director	no data	CN¥320.00k	データなし
Ronggang Xie	Non-Executive Director	5.4yrs	データなし	データなし
Yan Xu	Independent Non-Executive Director	no data	CN¥320.00k	データなし
Junwen Zeng	Independent Non-Executive Director	no data	CN¥320.00k	データなし

6.2yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: AKES.Fの取締役会は経験豊富であると考えられます ( 6.2年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/01/28 15:47
終値	2026/01/26 00:00
収益	2025/06/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Akeso, Inc. 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。39

アナリスト	機関
Rebecca Liang	Bernstein
Ethan Cui	BofA Global Research
Shun Kei Law	CCB International Securities Limited

Akeso マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Akeso, Inc., Annual General Meeting, Jun 30, 2025

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

Akeso, Inc. Announces Change of Directors

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc., Annual General Meeting, Jun 28, 2023

Recent updates

Akeso, Inc. Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis

Akeso, Inc. Announces Presentation of Real-World Study At the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Akeso, Inc. Announces the National Medical Products Administration Approves Significant Label Update in China for its Internally Develop, PD-1/VEGF Bispecific Antibody, ivonescimab

Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab

Akeso, Inc. Announces Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented atESMO IO 2025

Akeso, Inc. Announces Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia Congress

Akeso, Inc.'s Bispecific Antibody Targeting Aß and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China

Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer

Akeso, Inc. Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (Ak135) At SITC 2025

Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer

Summit Therapeutics Inc. Announces Results from the Phase III Harmoni-A Trial, Conducted in China and Sponsored by Akeso, Inc

Akeso Announces Results of the Registrational Phase III Clinical Study Evaluating Ivonescimab (PD-1/VEGF Bispecific Antibody)

HARMONi-6 Phase III Study of Ivonescimab Accepted by the Lancet and Selected for ESM0 2025 LBA Presentation

Akeso Inc. Announces Late-Breaking abstract (LBA) from the Registrational Phase III Clinical Study (AK-306/HARMONi-6 Study) of Ivonescimab

Akeso, Inc. Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-b Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer

Akeso, Inc. Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma

Akeso Inc. Announces Data from a Phase Ib/II Clinical Study Evaluating the Combination of Cadonilimab and Pulocimab (VEGFR-2) in Patients with Immunotherapy (IO-Resistant NSCLC)

Akeso, Inc. Announces HARMONi-A Study Conducted in China Reaches OS Clinical Endpoint

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.521667 billion.

Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.970287 billion.

Akeso Inc. Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4Ra) for Atopic Dermatitis Achieve Primary Endpoints

Akeso, Inc. Announces First Patient Dosed in Pivotal Phase Iii Trial of Cadonilimab (Pd-1/Ctla-4) for Perioperative Treatment of Resectable Gastric Cancer

Akeso, Inc. to Report First Half, 2025 Results on Aug 26, 2025

Akeso, Inc. Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

Akeso, Inc. Announces Approval to Initiate Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma

Akeso, Inc. Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC

National Medical Products Administration Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

Akeso, Inc. Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

Akeso, Inc. Announces First Patient Enrolled in the Phase III Trial (AK112-312/HARMONi-GI6) of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

Akeso's First Bispecific Adc (Trop2/Nectin4 Adc) Enters Clinical Trials, Strengthening Leadership in 'Io+Adc'2.0 Strategy

Akeso, Inc. Presents Subgroup Analysis Data from the Phase III Company-16 Trial

Akeso, Inc., Annual General Meeting, Jun 30, 2025

Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations

Akeso, Inc. Announces Its Globally First-In-Class PD-1/VEGF Bispecific Antibody, Ivonescimab, Received Approval from the National Medical Products Administration

Akeso, Inc. Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

Summit Therapeutics Inc. Announces Phase Iii Clinical Trial, Harmoni-6

Akeso's Ebdarokimab Receives Marketing Approval from the National Medical Products Administration

Akeso, Inc. to Report Fiscal Year 2024 Results on Mar 30, 2025

Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

Akeso, Inc. Announces the Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet

Akeso Announces Completion of Patient Enrollment in the Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

Akeso, Inc. Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

Akeso, Inc. Enrolles First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer

Akeso, Inc. Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Ra and ST2 for Respiratory and Skin Diseases

Akeso, Inc. Announces Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Current or Sequential Chemoradiotherapy in NSCLC

Akeso, Inc. Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab

Akeso, Inc.'s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accept by NMPA

Akeso, Inc. Publishes Results for Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer

Akeso Announces the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab

Akeso, Inc.'s Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma Accepted by NMPA

Akeso, Inc. Publishes Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.942576 billion.

Akeso Biopharma Announces Positive Results in Progression-Free Survival (PFS) and Overall Survival (OS) from Its Phase 3 Clinical Study

Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population

Akeso, Inc. Secures Approval from China’s National Medical Products Administration for Ebronucimab, Expanding Treatment Options for Hypercholesterolemia

Akeso's Ivonescimab Plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety At ESMO 2024

Akeso, Inc. to Report Q2, 2024 Results on Aug 28, 2024

Akeso, Inc. Announces Ivonescimab (Pd-1/Vegf) Received Priority Review from China's Nmpa for First-Line Treatment of Pd-L1 Positive Nsclc

Akeso, Inc. Announces That the First Patient Enrolled in the US Phase 2 Combination Therapy of it's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

Akeso's Sbla for Ivonescimab in 1L Treatment of Pd-L1 Positive Nsclc Accepted by NMPA

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

Akeso, Inc. Announces Change of Directors

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

マネジメント基準チェック /44